Effects of Reimbursement Add-On Policies on Trastuzumab and Bevacizumab Biosimilar Adoption in a Japanese Oncology Setting

IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES
Hiroaki Mamiya PhD, MPH , Toshiki Fukasawa PhD , Koji Kawakami MD, PhD
{"title":"Effects of Reimbursement Add-On Policies on Trastuzumab and Bevacizumab Biosimilar Adoption in a Japanese Oncology Setting","authors":"Hiroaki Mamiya PhD, MPH ,&nbsp;Toshiki Fukasawa PhD ,&nbsp;Koji Kawakami MD, PhD","doi":"10.1016/j.vhri.2025.101090","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>The Japanese government has introduced reimbursement incentive policies designed to promote biosimilar adoption for oncology biologics, including the provision of a financial incentive of ¥1500 (approximately $10) per prescription to physicians who prescribe biosimilars. This study aimed to evaluate the impact of Japan’s reimbursement policies on the uptake of oncology biosimilars, specifically trastuzumab and bevacizumab, in the outpatient setting.</div></div><div><h3>Methods</h3><div>We conducted an interrupted time series analysis using the health insurance claims database to assess the impact of the policy on biosimilar uptake, comparing trends before and after the policy intervention.</div></div><div><h3>Results</h3><div>The analysis incorporated 22 440 trastuzumab and 14 022 bevacizumab claims. For trastuzumab, interrupted time series analysis showed a significant slope change after policy implementation, with a slope change of 0.33% per month (95% CI 0.07-0.58). In contrast, bevacizumab did not exhibit significant changes in slope or level postintervention; however, its biosimilar uptake steadily increased over the entire study period.</div></div><div><h3>Conclusions</h3><div>This study suggests that reimbursement incentives have significantly enhanced the uptake of trastuzumab biosimilars in Japan, whereas bevacizumab has not exhibited a similar response. Given these findings, it is crucial for policy makers to design reimbursement strategies that are specifically tailored to the characteristics of each biosimilar to optimize their effectiveness.</div></div>","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":"46 ","pages":"Article 101090"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Value in health regional issues","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212109925000159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

The Japanese government has introduced reimbursement incentive policies designed to promote biosimilar adoption for oncology biologics, including the provision of a financial incentive of ¥1500 (approximately $10) per prescription to physicians who prescribe biosimilars. This study aimed to evaluate the impact of Japan’s reimbursement policies on the uptake of oncology biosimilars, specifically trastuzumab and bevacizumab, in the outpatient setting.

Methods

We conducted an interrupted time series analysis using the health insurance claims database to assess the impact of the policy on biosimilar uptake, comparing trends before and after the policy intervention.

Results

The analysis incorporated 22 440 trastuzumab and 14 022 bevacizumab claims. For trastuzumab, interrupted time series analysis showed a significant slope change after policy implementation, with a slope change of 0.33% per month (95% CI 0.07-0.58). In contrast, bevacizumab did not exhibit significant changes in slope or level postintervention; however, its biosimilar uptake steadily increased over the entire study period.

Conclusions

This study suggests that reimbursement incentives have significantly enhanced the uptake of trastuzumab biosimilars in Japan, whereas bevacizumab has not exhibited a similar response. Given these findings, it is crucial for policy makers to design reimbursement strategies that are specifically tailored to the characteristics of each biosimilar to optimize their effectiveness.
报销附加政策对曲妥珠单抗和贝伐珠单抗生物类似药在日本肿瘤环境采用的影响
日本政府推出了旨在促进肿瘤生物仿制药采用的报销激励政策,包括向开生物仿制药的医生提供每张处方1500日元(约10美元)的财政激励。本研究旨在评估日本报销政策对肿瘤生物仿制药(特别是曲妥珠单抗和贝伐单抗)在门诊使用的影响。方法利用健康保险理赔数据库进行中断时间序列分析,评估政策对生物仿制药使用的影响,比较政策干预前后的趋势。结果该分析纳入了22 440个曲妥珠单抗和14 022个贝伐单抗申请。对于曲妥珠单抗,中断时间序列分析显示,政策实施后斜率变化显著,斜率变化为每月0.33% (95% CI 0.07-0.58)。相比之下,贝伐单抗在干预后没有表现出显著的斜率或水平变化;然而,在整个研究期间,其生物类似药的吸收稳步增加。本研究表明,报销激励显著提高了曲妥珠单抗生物类似药在日本的吸收,而贝伐单抗没有表现出类似的反应。鉴于这些发现,决策者设计针对每种生物类似药的特点量身定制的报销策略以优化其有效性是至关重要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Value in health regional issues
Value in health regional issues Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
2.60
自引率
5.00%
发文量
127
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信